Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | UTS2R | Q9UKP6 | 7/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | AHCY | P23526 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10243510 | 0.88 | ALOX5 (0.40) | L3MBTL1UTS2RCNR1SMN1; SMN2 | |
| SCHEMBL10243623 | 0.87 | HPGD (0.40) | MAPTMTNR1AMTNR1BCYP2D6CYP2C9 | |
| SCHEMBL10244079 | 0.87 | ALDH1A1 (0.40) | MAPTL3MBTL1SMN1; SMN2HTTKMT2A | |
| SCHEMBL10243491 | 0.87 | MEN1 (0.45) | L3MBTL1CNR1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL10244037 | 0.87 | CYP1A2 (0.46) | MTNR1AMTNR1BUTS2RCNR1CYP2D6 | |
| SCHEMBL10243497 | 0.86 | SLC22A1 (0.43) | MTNR1AMTNR1BCNR1CYP2D6SMN1; SMN2 | |
| SCHEMBL10243444 | 0.85 | RAB9A (0.45) | MAPTCYP2C9CYP2C19SMN1; SMN2MEN1 | |
| SCHEMBL10243580 | 0.85 | ACACB (0.49) | CYP2D6SMN1; SMN2 | |
| SCHEMBL10244695 | 0.84 | SMN1; SMN2 (0.41) | MAPTL3MBTL1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL10243544 | 0.84 | LMNA (0.43) | CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | MAPT 4302/4885MTNR1A 2892/4885MTNR1B 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.